Effect of low dose recombinant human omega erythropoietin (rHuEPO) on anaemia in patients on hemodialysis.
Artículo
en Inglés
| IMSEAR
| ID: sea-88564
ABSTRACT
The effect of low dose rHuEPO therapy in ESRD patients on regular dialysis therapy was assessed in a prospective study in 22 patients. Routine hematological and biochemical tests, bone marrow aspiration, serum iron and ferritin studies were performed. The quality of life was also assessed. rHuEPO was administered in a dose of 25 units/kg i.v. post dialysis 3 times a week for 8 weeks, followed by 36 units/kg for further 4 weeks. Significant rise (p = 0.0001) in Hb & PCV with rise in reticulocyte count (0.016) was noted. Serum ferritin was a better index of iron status of the body. Significantly improved anemia and quality of life of ESRD patients on hemodialysis was seen in 95% of the patients.
Texto completo:
Disponible
Índice:
IMSEAR (Asia Sudoriental)
Asunto principal:
Calidad de Vida
/
Presión Sanguínea
/
Proteínas Recombinantes
/
Anciano
/
Humanos
/
Hemoglobinas
/
Estudios Prospectivos
/
Estudios de Seguimiento
/
Eritropoyetina
/
Diálisis Renal
Tipo de estudio:
Estudio observacional
/
Estudio pronóstico
/
Factores de riesgo
Idioma:
Inglés
Año:
1995
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS